Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Rectal Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Oropharyngeal Neoplasms 1 Lymphoma, Follicular 1 Leukemia, Hairy Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Burkitt Lymphoma 1 Anus Neoplasms 1

Interventions

Cyclophosphamide 23 Vincristine 16 Prednisone 16 Methotrexate 15 prednylidene 13 deltacortene 13 blinatumomab 13 merphos 12 Specimen Handling 12 Cytarabine 12 N,N-dicyclohexyl-isoborneol-10-sulfonamide 10 Mercaptopurine 10 Doxorubicin 10 Dexamethasone 10 pegaspargase 9 azathiopurine 9 Etoposide 9 Biopsy 9 dexamethasone acetate 8 dexamethasone 21-phosphate 8 auricularum 8 Spinal Puncture 8 Rituximab 8 Calcium Dobesilate 8 venetoclax 7 fludarabine 7 Leucovorin 7 Thioguanine 6 Magnetic Resonance Spectroscopy 6 Daunorubicin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Burkitt Lymphoma × Diphenhydramine × 30 days × Clear all

NCT07570173 2026-05-26

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡